แบบแสดงรายการข้อมูลการเสนอขายตราสารหนี้ 1 แบบแสดงรายการขอ้มลูและรา่งหนงัสอืชีช้วนส าหรบัการออกและเสนอขายตราสารหนี ้ ทีอ่อกและเสนอขายโดยนติบิคุคลตา่งประเทศ Registration Statement for Issuing and Offering of Debt Securities by Foreign Issuer Commercial Name of the Issuer……………………………………….. Offering to…………………………………………………………………….. Features of Debt Securities i.e. interest rate/ offering unit /total principle amount/ par value per unit/offering price per unit etc. Credit Rating…………………………………………………………………...
to 7.5%; Underperform where an ETR less than or equal to 5%. A Neutral may be assigned where the ETR is between - 5% and 15%. The overlapping rating range allows analysts to assign a rating that puts
demanding for all debt repayment. The Board of Directors issued the meeting resolution No.12/2018 dated November 9, 2018 to appoint OCAMPO & SURALVO LAW which is a legal advisor in the Philippines to claim
, and how the management company proceeds in case of failure to appoint a new guarantor; (c) Should the investors consider the risk from future credit of the guarantor or not, and how? Division 3 Mutual
November 9, 2018 to appoint OCAMPO & SURALVO LAW which is a legal advisor in the Philippines to claim against NPSI for the refund of capital investment. Currently, it is on the legal process. 3. Investment
dated November 9, 2018 to appoint OCAMPO & SURALVO LAW which is a legal advisor in the Philippines to claim against NPSI for the refund of capital investment. Currently, it is on the legal process. 3
than 100 percent. The details of which are as follows: Consequently, the Company is required to appoint the independent financial advisor responsible for giving opinions regarding the Transaction of
, 2018 demanding for all debt repayment. The Board of Directors issued the meeting resolution No.12/2018 dated November 9, 2018 to appoint OCAMPO & SURALVO LAW which is a legal advisor in the Philippines
offered monthly remuneration of Baht 0.60 million. According to the resolution of the Board of director’s meeting No.1/2018, which was held on February 21, 2018, approving to appoint Vitaya Leelawat, M.D
Directot After entering into the transaction, the Company shall appoint 2 persons as the Company’s representatives holding a position of NEXT’s director who are authorized, altogether with the existing